India, Nov. 12 -- Thursday, Vivani Medical, Inc. (VANI) announced positive top-line results from SLIM-1, its first-in-human Phase 1 trial evaluating NPM-139, an investigational long-acting semaglutide implant, against weekly Wegovy injections in overweight and obese participants.
NPM-139 is a subdermal implant designed to provide semaglutide delivery for chronic weight management through once- or twice-yearly administration using Vivani's proprietary NanoPortal technology.
SLIM-1 Phase 1 Results
The four-week study evaluated 10 participants receiving NPM-139 and 10 participants receiving the starting dose of Wegovy (0.25 mg weekly).
NPM-139 demonstrated a favourable safety and tolerability profile, with no treatment-related adverse even...